User contributions for Kosar Doraghi
Jump to navigation
Jump to search
3 May 2024
- 22:5722:57, 3 May 2024 diff hist +11,950 N Xacduro- sulbactam and durlobactam Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin..." current
1 May 2024
- 15:4615:46, 1 May 2024 diff hist +15,269 N Nirsevimab Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo..." current
- 15:3115:31, 1 May 2024 diff hist 0 N File:IMG 1185.jpeg No edit summary current
- 15:2915:29, 1 May 2024 diff hist 0 N File:IMG 1187.jpeg No edit summary current
27 April 2024
- 00:4900:49, 27 April 2024 diff hist +2,903 Chronic obstructive pulmonary disease history and symptoms No edit summary current
24 April 2024
- 23:1723:17, 24 April 2024 diff hist +5,051 Endocarditis overview No edit summary current
- 23:0423:04, 24 April 2024 diff hist 0 N File:IMG 1177.jpeg No edit summary current
- 22:5922:59, 24 April 2024 diff hist 0 N File:IMG 1176.jpeg No edit summary current
21 April 2024
- 04:0304:03, 21 April 2024 diff hist +198 BRENZAVVY- bexagliflozin No edit summary current
- 03:4803:48, 21 April 2024 diff hist 0 N File:IMG 1052.jpeg No edit summary current
- 03:4703:47, 21 April 2024 diff hist +12,083 N BRENZAVVY- bexagliflozin Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re..."
- 03:4303:43, 21 April 2024 diff hist 0 N File:IMG 1050.jpeg No edit summary current
- 03:4003:40, 21 April 2024 diff hist 0 N File:IMG 1051.jpeg No edit summary current
- 03:3403:34, 21 April 2024 diff hist 0 N File:IMG 1049.jpeg No edit summary current
19 April 2024
- 20:0320:03, 19 April 2024 diff hist +129 Template:KDRG No edit summary current
- 19:5319:53, 19 April 2024 diff hist −69 Template:KDRG No edit summary
- 16:3016:30, 19 April 2024 diff hist +8,644 N Sparsentan Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox..." current
- 16:2416:24, 19 April 2024 diff hist 0 N File:IMG 1046.jpeg No edit summary current
- 16:1416:14, 19 April 2024 diff hist 0 N File:IMG 1045.jpeg No edit summary current
- 16:1116:11, 19 April 2024 diff hist 0 N File:IMG 1047.jpeg No edit summary current
- 16:0516:05, 19 April 2024 diff hist 0 N File:IMG 1044.jpeg No edit summary current
18 April 2024
- 06:1806:18, 18 April 2024 diff hist +2,588 Endocarditis overview No edit summary
17 April 2024
- 04:2004:20, 17 April 2024 diff hist +9,001 Endocarditis overview No edit summary
10 April 2024
- 19:3119:31, 10 April 2024 diff hist +177 Endocarditis overview No edit summary
- 19:2019:20, 10 April 2024 diff hist 0 N File:IMG 1037.jpeg No edit summary current
3 April 2024
- 23:3123:31, 3 April 2024 diff hist +150 Endocarditis overview No edit summary
- 23:2823:28, 3 April 2024 diff hist 0 N File:IMG 0918.jpeg No edit summary current
- 23:2523:25, 3 April 2024 diff hist +3,293 Endocarditis overview No edit summary
21 March 2024
- 06:0106:01, 21 March 2024 diff hist +195 Ryzneuta No edit summary current
- 05:5805:58, 21 March 2024 diff hist 0 N File:IMG 0885.jpeg No edit summary current
19 March 2024
- 23:0823:08, 19 March 2024 diff hist +8 Ryzneuta No edit summary
- 23:0723:07, 19 March 2024 diff hist +10,751 N Ryzneuta Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com]] |genericName=RYZNEUTA -Efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=treatment |indication=and decrease the incidence of infection, as manifested by [febrile neutropenia], in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |h..."
- 21:4421:44, 19 March 2024 diff hist +43 Nedosiran No edit summary current
5 March 2024
- 01:4701:47, 5 March 2024 diff hist +21,576 Endocarditis overview No edit summary
28 February 2024
- 02:4002:40, 28 February 2024 diff hist +23,635 N Vonoprazan fumarate Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=vonoprazan fumarate |aOrAn=a |drugClass=potassium-competitive acid blocker |indicationType=treatment |indication=all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. *to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. *in combinatio..." current
24 February 2024
- 20:4420:44, 24 February 2024 diff hist +513 Template:KDRG No edit summary
23 February 2024
- 21:3621:36, 23 February 2024 diff hist +8,159 N Nedosiran Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=nedosiran |aOrAn=an |drugClass=LDHA-directed small interfering RNA |indicationType=treatment |indication=lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥ 30 mL/min/1.73 m2 |adverseReactions=injection site reactions |fdaLIADAdult=RIVFLOZA Injection 160 mg/mL is a clear, colorless-t..."
- 21:2521:25, 23 February 2024 diff hist 0 N File:IMG 0866.jpeg No edit summary current
- 21:2421:24, 23 February 2024 diff hist 0 N File:IMG 0864.jpeg No edit summary current
- 21:2121:21, 23 February 2024 diff hist 0 N File:IMG 0858.jpeg No edit summary current
- 21:2021:20, 23 February 2024 diff hist 0 N File:IMG 0861.jpeg No edit summary current
- 21:2021:20, 23 February 2024 diff hist 0 N File:IMG 0860.jpeg No edit summary current
- 21:1921:19, 23 February 2024 diff hist 0 N File:IMG 0859.jpeg No edit summary current
- 21:1721:17, 23 February 2024 diff hist 0 N File:IMG 0867.jpeg No edit summary current
- 21:1121:11, 23 February 2024 diff hist 0 N File:IMG 0857.jpeg No edit summary current
- 21:0921:09, 23 February 2024 diff hist 0 N File:IMG 0856.jpeg No edit summary current
- 21:0621:06, 23 February 2024 diff hist 0 N File:IMG 0855.jpeg No edit summary current
- 21:0521:05, 23 February 2024 diff hist 0 N File:IMG 0853.jpeg No edit summary current
- 20:5320:53, 23 February 2024 diff hist 0 N File:IMG 0852.jpeg No edit summary current
- 04:1604:16, 23 February 2024 diff hist +15,630 N Nirogacestat Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=nirogacestat |aOrAn=a |drugClass=gamma secretase inhibitor |indicationType=treatment |indication=adult patients with progressing desmoid tumors who require systemic treatment |hasBlackBoxWarning=Yes |adverseReactions=diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection and [..." current
- 04:0504:05, 23 February 2024 diff hist 0 N File:IMG 0851.jpeg No edit summary current
- 04:0004:00, 23 February 2024 diff hist 0 N File:IMG 0848.jpeg No edit summary current
- 03:5903:59, 23 February 2024 diff hist 0 N File:IMG 0850.jpeg No edit summary current
- 03:5703:57, 23 February 2024 diff hist 0 N File:IMG 0847.jpeg No edit summary current
16 February 2024
- 03:1503:15, 16 February 2024 diff hist +9,988 N Lasmiditan Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Lasmiditan (REYVOW) |aOrAn=a |drugClass=serotonin (5-HT) 1F receptor agonist |indicationType=treatment |indication=migraine with or without aura in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, fatigue, paresthesia, and sedation |blackBoxWarningTitle=Warning |blackBoxWarningBody=Driving Impairment: *Central Nervous System (CNS) Depression: Do not use in combination..." current
- 03:0303:03, 16 February 2024 diff hist 0 N File:IMG 0837.jpeg No edit summary current
- 02:5802:58, 16 February 2024 diff hist 0 N File:IMG 0839.jpeg No edit summary current
- 02:5602:56, 16 February 2024 diff hist 0 N File:IMG 0838.jpeg No edit summary current
15 February 2024
- 02:4502:45, 15 February 2024 diff hist +16 Ponesimod No edit summary current
- 01:0101:01, 15 February 2024 diff hist +19,062 N Ponesimod Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Ponesimod (PONVORY) |aOrAn=a |drugClass=sphingosine 1-phosphate receptor modulator |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=upper respiratory tract infection, hepatic transaminase elevation, and ..."
- 00:5600:56, 15 February 2024 diff hist 0 N File:IMG 0834.jpeg No edit summary current
- 00:5500:55, 15 February 2024 diff hist 0 N File:IMG 0833.jpeg No edit summary current
- 00:4900:49, 15 February 2024 diff hist 0 N File:IMG 0832.jpeg No edit summary current
- 00:4800:48, 15 February 2024 diff hist 0 N File:IMG 0829.jpeg No edit summary current
- 00:4600:46, 15 February 2024 diff hist 0 N File:IMG 0831.jpeg No edit summary current
14 February 2024
- 18:3018:30, 14 February 2024 diff hist +12,162 N Dasiglucagon Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Dasiglucagon (ZEGALOGUE) |aOrAn=an |drugClass=anti-hypoglycemic |indicationType=treatment |indication=severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, headache, diarrhea, and injection site pain |blackBoxWarningTitle=Allergic reactions |blackBoxWarningBody=increase in blood pressure in Patients wi..." current
- 18:1718:17, 14 February 2024 diff hist 0 N File:IMG 0828.jpeg No edit summary current
- 18:1618:16, 14 February 2024 diff hist 0 N File:IMG 0827.jpeg No edit summary current
- 18:1318:13, 14 February 2024 diff hist 0 N File:IMG 0822.jpeg No edit summary current
- 18:1218:12, 14 February 2024 diff hist 0 N File:IMG 0826.jpeg No edit summary current
- 18:0718:07, 14 February 2024 diff hist 0 N File:IMG 0824.jpeg No edit summary current
- 18:0518:05, 14 February 2024 diff hist 0 N File:IMG 0823.jpeg No edit summary current
- 17:5917:59, 14 February 2024 diff hist 0 N File:IMG 0820.jpeg No edit summary current
- 17:5817:58, 14 February 2024 diff hist 0 N File:IMG 0819.jpeg No edit summary current
13 February 2024
- 22:0022:00, 13 February 2024 diff hist +356 Vericiguat No edit summary current
- 21:5721:57, 13 February 2024 diff hist 0 N File:IMG 0813.jpeg No edit summary current
- 21:5621:56, 13 February 2024 diff hist 0 N File:IMG 0812.jpeg No edit summary current
- 21:5421:54, 13 February 2024 diff hist 0 N File:IMG 0817.jpeg No edit summary current
- 21:5121:51, 13 February 2024 diff hist 0 N File:IMG 0818.jpeg No edit summary current
- 21:5021:50, 13 February 2024 diff hist 0 N File:IMG 0816.jpeg No edit summary current
- 21:4721:47, 13 February 2024 diff hist +11,303 N Vericiguat Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VERQUVO-vericiguat |aOrAn=a |drugClass=soluble guanylate cyclase (sGC) stimulator |indicationType=treatment |indication=heart failure with reduced ejection fraction (HFrEF), reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less t..."
- 21:4321:43, 13 February 2024 diff hist 0 N File:IMG 0815.jpeg No edit summary current
- 03:3003:30, 13 February 2024 diff hist +31 Tapinarof No edit summary current
- 03:2003:20, 13 February 2024 diff hist 0 N File:IMG 0810.jpeg No edit summary current
- 03:1803:18, 13 February 2024 diff hist +5,123 N Tapinarof Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VTAMA- tapinarof cream |aOrAn=an |drugClass=aryl hydrocarbon receptor agonist |indicationType=treatment |indication=plaque psoriasis in adults |adverseReactions=folliculitis, nasopharyngitis, contact dermatitis, headache, and pruritus |fdaLIADAdult=Cream, 1% Each gram of VTAMA cream contains 10 mg of tapinarof in a white to off-white cream. *Apply a thin layer of VTAMA cream to affected ar..."
- 03:1403:14, 13 February 2024 diff hist 0 N File:IMG 0809.jpeg No edit summary current
- 03:1203:12, 13 February 2024 diff hist 0 N File:IMG 0808.jpeg No edit summary current
- 03:1003:10, 13 February 2024 diff hist 0 N File:IMG 0807.jpeg No edit summary current
12 February 2024
- 17:4017:40, 12 February 2024 diff hist +1,888 N Spevigo- spesolimab-sbz Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=spesolimab-sbzo |aOrAn=an |drugClass=interleukin-36 receptor antagonis |indicationType=treatment |indication=generalized pustular psoriasis flares in adults |hasBlackBoxWarning=Yes |adverseReactions=asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection. |blackBoxWarningTitle=Warning: Hyp..." current
10 February 2024
- 06:1706:17, 10 February 2024 diff hist +22,457 N Ublituximab-xiiy Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=BRIUMVI™ (ublituximab-xiiy |aOrAn=a |drugClass=CD20-directed cytolytic antibody |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion reactions and upper respiratory..." current
- 06:1406:14, 10 February 2024 diff hist 0 N File:IMG 0806.jpeg No edit summary current
- 06:1306:13, 10 February 2024 diff hist 0 N File:IMG 0805.jpeg No edit summary current
- 06:0906:09, 10 February 2024 diff hist 0 N File:IMG 0799.jpeg No edit summary current
7 February 2024
- 17:1517:15, 7 February 2024 diff hist +20,864 N LYTGOBI- futibatinib Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Futibatinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is approved under accelerated approval based on overall respons..." current
- 05:0305:03, 7 February 2024 diff hist 0 N File:IMG 0790.jpeg No edit summary current
- 05:0105:01, 7 February 2024 diff hist 0 N File:IMG 0787.jpeg No edit summary current
- 04:5604:56, 7 February 2024 diff hist 0 N File:IMG 0788.jpeg No edit summary current
6 February 2024
- 22:3122:31, 6 February 2024 diff hist +418 Deucravacitinib No edit summary current
- 22:1722:17, 6 February 2024 diff hist 0 N File:IMG 0786.jpeg No edit summary current
- 22:0722:07, 6 February 2024 diff hist 0 N File:IMG 0785.jpeg No edit summary current
- 22:0522:05, 6 February 2024 diff hist 0 N File:IMG 0782.jpeg No edit summary current
- 21:4521:45, 6 February 2024 diff hist 0 N File:IMG 0783.jpeg No edit summary current
- 21:4421:44, 6 February 2024 diff hist 0 N File:IMG 0784.jpeg No edit summary current
- 21:1821:18, 6 February 2024 diff hist +25,798 N Deucravacitinib Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Deucravacitinib (SOTYKTU) |aOrAn=a |drugClass=tyrosine kinase 2 (TYK2) inhibitor |indicationType=treatment |indication=treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |hasBlackBoxWarning=Yes |adverseReactions=hypersensitivity reaction, upper respiratory infections, blood creatine phosphokinase increased,..."
5 February 2024
- 23:3423:34, 5 February 2024 diff hist +2 RELYVRIO No edit summary current
- 06:3706:37, 5 February 2024 diff hist +1 RELYVRIO No edit summary
- 06:3406:34, 5 February 2024 diff hist −8 RELYVRIO No edit summary
- 06:3206:32, 5 February 2024 diff hist +56 RELYVRIO No edit summary
- 06:2506:25, 5 February 2024 diff hist +189 RELYVRIO No edit summary
- 06:0006:00, 5 February 2024 diff hist 0 N File:IMG 0781.jpeg No edit summary current
- 05:5205:52, 5 February 2024 diff hist −23 RELYVRIO No edit summary
- 05:4905:49, 5 February 2024 diff hist +14,763 N RELYVRIO Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=sodium phenylbutyrate/taurursodiol |aOrAn=a |drugClass=drug that containing the active ingredients sodium phenylbutyrate and taurursodiol |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults. |hasBlackBoxWarning=Yes |adverseReactions=diarrhea, abdominal discomfort , nausea, and upper respiratory tract infection |blackBo..."
- 05:0505:05, 5 February 2024 diff hist 0 N File:IMG 0779.jpeg No edit summary current
- 05:0405:04, 5 February 2024 diff hist 0 N File:IMG 0780.jpeg No edit summary current
4 February 2024
- 23:1123:11, 4 February 2024 diff hist 0 N File:IMG 0777-sodium phenylbutyrate.jpeg No edit summary current
2 February 2024
- 21:4021:40, 2 February 2024 diff hist +12 NEXOBRID No edit summary current
- 21:3421:34, 2 February 2024 diff hist +56 NEXOBRID No edit summary
- 21:0821:08, 2 February 2024 diff hist +84 NEXOBRID No edit summary
- 20:5620:56, 2 February 2024 diff hist 0 N File:Nexobrid-02.jpg No edit summary current
- 20:4420:44, 2 February 2024 diff hist 0 N File:Nexobrid-01.jpg No edit summary current
- 04:1704:17, 2 February 2024 diff hist +29 NEXOBRID No edit summary Tag: Visual edit: Switched
- 03:5103:51, 2 February 2024 diff hist +19,139 N NEXOBRID Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. |genericName=anacaulase-bcdb |aOrAn=a |indicationType=treatment |indication=eschar in adults with deep partial thickness or full thickness thermal burns. The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns, burns on the face, perineum, or genitalia, burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular..."
30 January 2024
- 22:3222:32, 30 January 2024 diff hist +98 Cholesteatoma →Overview current Tag: Visual edit
18 January 2024
- 21:0721:07, 18 January 2024 diff hist +70 N Template:KDRG Created page with "Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com]"